doi:10.36849/JDD.9089

 ORIGINAL ARTICLE

PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact

Naiem T. Issa MD PhD,[a,b,c] Sabine Obagi BA,[d] Giovanni Damiani MD PhD,[e] Jimin Wang PhD,[f,g] Christopher G. Bunick MD PhD[f,g,h]

[a]Forefront Dermatology, Vienna, VA
[b]Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL
[c]Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC;
[d]College of Medicine, University of Arizona, Tucson, AZ; [e]Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy; [f]Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT;
[g]Department of Dermatology, Yale School of Medicine, New Haven, CT; [h]Program in Translational Biomedicine, Yale School of Medicine, New Haven, CT

ABSTRACT

Phosphodiesterase-4 (PDE4) inhibitors are reshaping the treatment landscape for chronic inflammatory skin diseases by offering effective, non-steroidal options for conditions like psoriasis, atopic dermatitis, and seborrheic dermatitis. This perspective translates recent structural biology and biochemical findings into clinically meaningful guidance. Among available agents, roflumilast stands out for its high potency and selectivity, with a half-maximal inhibitory concentration of 0.7 nM compared to 140 nM for apremilast (200-fold less) and 750 nM for crisaborole (1071-fold less). This higher potency enables lower dosing and improved tolerability, particularly in topical formulations. Unlike earlier PDE4 inhibitors, roflumilast's structural similarity to the second signal messenger cyclic adenosine monophosphate (cAMP) results in stronger binding to and inhibition of PDE4 and more effective suppression of inflammation. Clinically, this translates into rapid improvements in skin erythema, scaling, and itch, with minimal systemic side effects. Roflumilast is especially valuable for patients who are steroid-averse, pediatric, elderly, or have contraindications to systemic therapy. It can also be integrated into combination regimens, offering flexibility for refractory cases. As ongoing research explores its use in other skin conditions such as vitiligo and lichen planus, understanding the molecular differences among PDE4 inhibitors becomes increasingly relevant to the practicing dermatology provider. By connecting molecular pharmacology with therapeutic decision-making, this article supports dermatology clinicians in selecting targeted therapies that improve patient outcomes, adherence, and quality of life.

J Drugs Dermatol. 2025;24(6):631-633. doi:10.36849/JDD.9089

INTRODUCTION

Phosphodiesterase-IV (PDE4) inhibitors represent a burgeoning frontier in dermatological care, offering targeted solutions to inflammatory skin diseases such as psoriasis, atopic dermatitis, and seborrheic dermatitis. PDE4 inhibitors function by increasing cyclic adenosine monophosphate (cAMP), leading to reduced inflammation via cytokine suppression.[1] This perspective highlights the practical implications of a recent study[2] analyzing the chemical, biochemical, and structural nuances of PDE4 inhibitors – roflumilast, apremilast, and crisaborole – and translates these insights for dermatology clinicians aiming to optimize patient outcomes.

Why PDE4 Inhibition Matters in Dermatology

Inflammatory skin diseases arise from complex immune dysregulation involving Th1, Th2, Th22, and Th17 cytokine pathways.[3] PDE4 is a key enzyme expressed in immune and epithelial cells that regulates these pathways by breaking down cAMP, a molecule integral to anti-inflammatory signaling.[4] PDE4 inhibitors extend cAMP's action, thereby reducing inflammation and restoring immune balance.

The introduction of roflumilast, a potent and selective PDE4 inhibitor, offers distinct clinical advantages. Unlike earlier PDE4 inhibitors such as apremilast (oral) and crisaborole (topical), roflumilast boasts significantly higher potency, allowing for more effective treatment of inflammatory skin conditions (Figure 1).[2]

FIGURE 1. PDE4 inhibitors target multiple inflammatory pathways, including Th1, Th2, Th22, and Th17 inflammation, and restore skin barrier integrity.

Key Findings and Practical Implications

1. Higher Potency and Selectivity of Roflumilast

The study reports the half-maximal inhibitory concentration (IC50) values of 0.7 nM for roflumilast, compared with 140 nM for apremilast (200-fold less) and 750 nM for crisaborole (1071-fold less).[2,5] This striking difference translates clinically into lower required doses of roflumilast to achieve therapeutic effects, potentially reducing systemic side effects. Additionally, roflumilast's high selectivity for PDE4B/D minimizes off-target interactions, ensuring its safety profile is well-suited for chronic inflammatory skin diseases.

Practical Tip: For patients with mild-to-moderate atopic dermatitis or psoriasis who have failed to respond adequately to topical steroids, roflumilast cream or foam is an optimal next step before considering systemic therapies or phototherapy.

2. Apremilast: Limited Efficacy for Psoriasis

While apremilast offers the convenience of oral administration, its efficacy in treating psoriasis is limited based on clinical trials and indirect network meta-analysis (NMA).[15] The IC_{50} value of 140 nM reflects its weaker inhibition of PDE4, which often translates to slower and less robust clinical improvement. Moreover, gastrointestinal (GI) side effects (nausea, diarrhea) associated with systemic administration often limit adherence.[7] In contrast, biologics like IL-23 or IL-17 inhibitors offer higher clearance rates and long-term disease control for moderate-to-severe psoriasis as demonstrated in NMA.[8,9,10] However, of the IL-23 and IL-17 biologics, only risankizumab (an IL-23 inhibitor) has demonstrated in a head-to-head clinical trial superior efficacy to oral apremilast in terms of skin clearance and optimal long-term disease control for moderate and severe psoriasis.[8,10,16]

Clinical Insight: Apremilast can be used for mild-to-moderate psoriasis or patients unable to tolerate biologics, but it is less effective compared with newer alternatives like IL-23 or IL-17 inhibitors.[15.16]

3. Enhanced Mechanism of Action

Roflumilast's structural design closely mimics cAMP, allowing it to bind PDE4 more tightly and effectively inhibit inflammatory responses. Crisaborole, in contrast, mimics phosphate but lacks optimal interaction with the PDE4 active site, reducing its potency.[2]

Clinical Insight: This mechanism explains why roflumilast provides rapid relief of itch and erythema in inflammatory skin conditions.

4. Improved Formulations for Patient Adherence

Unlike oral apremilast (associated with GI and psychiatric side effects) and crisaborole (which commonly causes stinging upon application), roflumilast's topical cream and foam formulations provide a patient-friendly alternative with high tolerability and the only contraindication being moderate to severe liver impairment categorized as Child-Pugh B or C.[11]

Practical Tip: Educating patients on roflumilast's tolerability and non-steroidal nature can increase adherence, especially in pediatric and sensitive-skin patients.

Broader Clinical Implications

Expanding Indications

Roflumilast is already FDA-approved for the treatment of plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, but emerging data suggest efficacy in other inflammatory conditions[12] such as vitiligo[13] and lichen planus.[14]

Integration Into Treatment Pathways

Roflumilast is an alternative to systemic treatments for patients who prefer topical therapy or have contraindications for systemic medications (eg, elderly patients, pediatric populations).[12]

Potential for Combination Therapy

Given its distinct mechanism, roflumilast can be combined with biologics or other targeted therapies to enhance outcomes for refractory cases given no drug-drug interactions according to the prescribing label.[11]

Practical Recommendations for Dermatology Clinicians

1. Start Small, Think Big: Use roflumilast cream or foam for localized psoriasis plaques or mild-to-moderate atopic dermatitis before escalating therapy.
2. Tailor Therapy: For patients worried about steroid-related side effects, roflumilast is a potent nonsteroidal option.
3. Monitor Outcomes: Emphasize itch relief and skin clearance, as these strongly correlate with patient satisfaction.

CONCLUSION

PDE4 inhibitors like roflumilast are redefining dermatological care, offering potent, well-tolerated, non-steroidal options for inflammatory skin diseases. Understanding their unique mechanisms and practical implications allows clinicians to elevate patient outcomes while minimizing adverse effects.

DISCLOSURES

NTI and CGB have served as consultants for Amgen, Arcutis, and Pfizer. None of the other authors have relevant disclosures.

REFERENCES

1. Dong C, Virtucio C, Zemska O, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors. *J Pharmacol Exp Ther.* 2016;358(3):413-422.
2. Wang J, Ho M, Bunick CG. Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors. *J Invest Dermatol.* 2024;S0022-202X(24)02885-9. doi:10.1016/j.jid.2024.10.597. PMID: 39608668.

3. Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. *J Am Acad Dermatol*. 2018;78(3 Suppl 1):S43-S52.
4. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. *Cell Signal*. 2014;26(9):2016-2029.
5. Jin J, Mazzacuva F, Crocetti L, et al. PDE4 inhibitors: profiling hits through the multitude of structural classes. *Int J Mol Sci*. 2023;24(14):11518.
6. Treichel A, Demeo D, Korman N, et al. Apremilast's cardioprotective effect in psoriasis. Abstract 2678. Presented at: EADV Congress 2024; September 2024, Amsterdam, The Netherlands.
7. Silverberg JI, French LE, Warren RB, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. *J Eur Acad Dermatol Venereol*. 2023;37(4):721-729.
8. Daniele SG, Eldirany SA, Damiani G, et al. Structural basis for p19 targeting by anti-IL-23 biologics: correlations with short- and long-term efficacy in psoriasis. *JID Innov*. 2024;4(2):100261. doi:10.1016/j.xjidi.2024.100261. PMID: 38445231.
9. Warren RB, Donnelly K, Kiri S, et al. Long-term efficacy and safety of bimekizumab and other biologics in moderate to severe plaque psoriasis: updated systematic literature review and network meta-analysis. *Dermatol Ther (Heidelb)*. 2024;14(11):3133-3147. doi:10.1007/s13555-024-01302-0. PMID: 39485596; PMCID: PMC11557745, PMC10914523.
10. Daniele SG, Galimberti F, Bunick CG. Structural insights: what makes some IL-23 biologics more effective in psoriasis. *J Drugs Dermatol*. 2024;23(10):903-904. PMID: 39361690.
11. Roflumilast (Daliresp) prescribing information. U.S. Food and Drug Administration. 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022522s009lbl.pdf. Accessed December 30, 2024.
12. Carmona-Rocha E, Rusiñol L, Puig L. Exploring the therapeutic landscape: a narrative review on topical and oral phosphodiesterase-4 inhibitors in dermatology. *Pharmaceutics*. 2025;17(1):91. doi:10.3390/pharmaceutics17010091. PMID: 39861739; PMCID: PMC11769339.
13. Warren K, Sanchez S. Recalcitrant pediatric facial vitiligo successfully treated with roflumilast cream 0.3% once daily. *J Clin Aesthet Dermatol*. 2025;18(1):52-54. PMID: 39830826; PMCID: PMC11741172.
14. Viswanath V, Joshi P, Dhakne M, et al. Evaluation of the efficacy and safety of apremilast in the management of lichen planus. *Clin Cosmet Investig Dermatol*. 2022;15:2593-2600. doi:10.2147/CCID.S390591.
15. Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. *JAMA Dermatol*. 2020;156(3):258-269.
16. Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). *Br J Dermatol*. 2023;189(5):540-552.

AUTHOR CORRESPONDENCE

Christopher G. Bunick MD PhD
E-mail:..... christopher.bunick@yale.edu